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Hyperglycemia in thrombo-
lysed acute ischemic stroke
patients
In a relatively small sample of acute
stroke patients treated with intravenous
tissue plasminogen activator (IV-tPA),
Meurer et al. (1) found no association
between admission hyperglycemia and
clinical outcomes (death, disability
and intracerebral hemorrhage (ICH)).
These results are counter to the conclu-
sions of several other studies of similar
size (2–4) and one larger prospective
cohort study that found a clear associa-
tion between admission hyperglycemia
and an increased risk of death, sympto-
matic ICH (sICH) and disability out-
comes (5). Thus, these results may
simply represent a type II error (accept-
ing the null-hypothesis when it should
be rejected).
However, other explanations for
these results should be considered.
Only in-hospital death was reported,
while other studies have generally ex-
amined mortality at 30 or 90 days. This
would presumably lead to fewer out-
come events in the current study and
potentially underestimate the associa-
tion between hyperglycemia and death,
assuming that hyperglycemia is asso-
ciated with an increased risk of death
beyond the early phase after stroke.
Similarly, considering disability at dis-
charge rather than at a later time point
may mask an eventual divergence in
functional outcome between hypergly-
cemic and nonhyperglycemic patients
over time. The use of the European
Cooperative Acute Stroke Study defi-
nition of sICH (parenchymal hemato-
ma type 2), resulted in a lower overall
sICH rate compared with the use of
the National Institute of Neurological
Disorders and Stroke IV-tPA trial defi-
nition, and this may have diluted the
association between glucose and sICH
in this study.
The rate of overall ICH (99%) was
surprisingly low as compared with other
studies (2, 5) and may help explain
the absence of an association between
hyperglycemia and ICH. It is also pos-
sible that the population studied was
comprised of milder strokes (median
baseline National Institutes of Health
Stroke Scale (NIHSS) is not provided)
or a preponderance of lacunar strokes, a
sub-type for which hyperglycemia may
be less deleterious – or even beneficial
(6). We found no evidence, on examin-
ing our own data, of effect modification
of hyperglycemia on poor outcomes by
baseline NIHSS score or by the Oxford-
shire Community Stroke Project stroke
type. Akin to the Meurer study, one
other group also found no association
between isolated admission hyperglyce-
mia and outcome. In that study, among
a mixed cohort of thrombolysed
and nonthrombolysed patients, only
persistent hyperglycemia at 24 h was
associated with worse outcome. Unfor-
tunately, 24 h glucose values were not
available in the Meurer study.
We believe that the association be-
tween admission hyperglycemia and
worse outcome in acute stroke
patients treated with IV-tPA is well
established and real. The more impor-
tant question is whether aggressively
treating hyperglycemia can improve
patient outcomes.
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We thank Drs Poppe and Hill for
insightful observations regarding our
study. Our a priori belief when initiating
this investigation was that we would
confirm the relationship between ele-
vated glucose and adverse outcomes
reported previously by others. After
our analysis did not confirm this rela-
tionship, we felt it was important to
provide this observation in order to
aid future researchers and increase the
amount of data available for systematic
reviews and meta-analyses.
The median NIHSS in our cohort was
13 – additional information regarding
other characteristics of the patients has
now been published, although TOAST
sub-typing was not carried out (1). We
did not collect data on 24 h glucose or 90
day disability. The longer term impact
of glucose on mortality could be eval-
uated in our data as we had follow-up
mortality data. Of the 273 patients in the
cohort, 112 had died through the end of
our study follow up in 2005. Based on
the suggestion, we examined 90 day
mortality using Cox’s proportional ha-
zards regression. The hazard ratio for
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each 100 mg/dl increase in glucose was
171 (95% confidence interval 11–27),
with NIHSS, age and smoking included
in accordance with the methods of the
final binary logistic regression models
reported in our paper. Not surprisingly,
this was very similar to our published
estimate of the association between glu-
cose and in-hospital mortality – with a
tighter confidence interval that no
longer includes one.
Of course, these findings may repre-
sent a type II error and/or a manifesta-
tion of either the design limitations we
noted in our manuscript or those listed
by Drs Poppe and Hill. Disagreement
between these data and prior studies
may also reflect a deeper problem. It
may be that all retrospective observa-
tions of the association between initial
glucose and outcome may over simplify
a complex pathology that defies simple
interpretations. After all, initial glucose
is a snapshot of a time-varying signal
that reflects a variety of pathologies and
comorbidities, and can result in physio-
logical responses that may differ from
patient to patient.
Based on all available clinical
and laboratory data, it is likely that
glucose metabolism interacts with acute
brain injury, but the nature of the
interaction requires further explora-
tion. Even the way that we examine the
available clinical observational data and
our prior assumptions may influence
interpretation. For example, should glu-
cose be modeled as a continuous vari-
able or should it be dichotomized as in
many prior studies? The statistician
in me says that dichotomization is
throwing away data. The clinician in
me has a difficult time conceptualizing
the adverse effects of one milligram
per deciliter rise in blood glucose.
Should we assume a linear response, or
should we model a U-shaped or an other
type of relationship? Ultimately, we
share Drs Poppe and Hill’s inclination
that hyperglycemia is adverse in brain
injury; however, we also recognize the
importance of keeping an open mind as
data continue to emerge and theories
are either confirmed or become more
complicated. We strongly support pro-
spective randomized trials of glucose-
lowering strategies.
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A new ultrasound method for
evaluating dysphagia in
acute stroke patients
Dysphagia after stroke was a common
and serious complication, and conven-
tional methodologies of swallowing
evaluation had several limitations.
Here, we examined tongue movement
during the swallowing process in order
to evaluate dysphagia with our unique
ultrasound examination, the Tongue
and Oral Function test with Ultrasound
(TOFU).
For 100 acute stroke patients (65 men,
7227107 years) in who swallowing
status had been evaluated by the mod-
ified water swallowing test and the food
test, we performed TOFU in addition
to videofluoroscopic swallowing study
(VFSS). Dysphagia was defined as
abnormal swallowing on VFSS. In
TOFU, a patient was requested to
swallow saliva in the 301 head-up posi-
tion. Tongue surface was visible as
a bright narrow line on an M-mode
image (Fig. 1) (1–5). We measured the
downward (Vd) and upward movement
velocities (Vu) of tongue in the swallow-
ing phase, and the distance from the
caudally depressed to the cranially ele-
vated positions (D). We assessed differ-
ences in various TOFU findings between
the 24 patients with dysphagia and 76
patients without, and configured a ROC
curve for Vu.
Vd and Vu were slower in the patients
with dysphagia than in those without (Vd,
380172142 vs. 479872075 mm/s,
P 5 0007; Vu, 570471624 vs. 85437
2474 mm/s, Po0001), and D was shorter
(11637319 vs. 13497355 mm, P 5
0027). With a cut-off value of Vu of
6355 mm/s, the sensitivity for the de-
tection of dysphagia was 833% and the
specificity was 882%.
A notable finding was that a cut-off
value of Vu of 6355 mm/s could
accurately predict dysphagia. The








Fig. 1 A representative sagittal B-mode and M-mode ultrasound image of the swallowing process
observed in a stroke patient without dysphagia. The viewing point of the tongue, marked by black star,
was recognizable by its horizontal trace during the preparatory phase on an M-mode image. It was
recognizable by the downward movement (Vd, white arrow), and then the upward movement (Vu,
black arrow) in the swallowing phase. The distance from the caudally depressed to the cranially-
elevated position was measured (D, gray double-headed arrow).
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